Talk:Ipratropium bromide/salbutamol

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ipratropium bromide/salbutamol.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Patent expiration?

Does anyone know whe the Patent expires, or how to find this information? —Preceding unsigned comment added by 204.77.52.227 (talk) 13:57, 28 January 2009 (UTC)[reply]

In general, U.S. patent expriation can be easily found in the US FDA Orange book: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm

Specifically, the patent for Combivent expires 09 Jun 2015. —Preceding unsigned comment added by 192.28.0.17 (talk) 21:17, 26 July 2010 (UTC)[reply]

"Confusing" tag response

I've moved the following (that seems like a response to the tag posted in 2009) here as that is what talk pages are for. Raykyogrou0 (Talk) 12:24, 11 January 2014 (UTC)[reply]

In response to the "confusing section", here are links to the controversy in question if someone more knowledgeable in this area would be so kind as to consolidate it and wrap it up, so to speak:

· Medicare Reimbursement of Physician-Administered Drugs^[1]

· Food & Drug Law Journal, 2009: Opacity and Cost Effectiveness Analysis in Medicare Coverate Decisions: Health Policy Encounters Administrative Law^[2]

· The Comparative Effectiveness Research Landscape in the United States and Its Relevance to the Medicare Program^[3]

Although [perhaps] unrelated, here is a recent FDA Safety Sheet for DuoNeb:.^[4]

References

[1] Medicare Reimbursement of Physician-Administered Drugs, House Hearing, 109th Congress, Serial No. 109-83

[2] Opacity and Cost Effectiveness Analysis in Medicare Coverate Decisions, 64 Food & Drug L.J. 515

[3] CMTP report for The Medicare Payment Advisory Commission, 31 May 2010

[4] FDA Safety Sheet for DuoNeb

[1]

[2]

[3]

[4]